Company: IXHL
Filing Date: 2025-04-28
Form Type: DEF 14A
Source: 0001213900-25-036057
Chunk: 16

Company: Incannex Healthcare Inc.
Filing Date: 2025-04-28
Form: DEF 14A
Chunk 16
---
347,222,700shares of common stock assuming full adjustment of the exercise price to the Floor Price and exercise pursuant to the zero exercise price provisions of the Series A Warrants as described below (the “Series A Warrant Shares” and together with the Pre -FundedWarrant Shares, the “Warrant Shares”) at an initial exercise price of $2.16 per share. The Pre -FundedWarrants are exercisable (in cash or by cashless exercise) for shares of common stock for a nominal exercise price of $0.0001 per Pre -FundedWarrant Share, were immediately exercisable upon issuance and expire when exercised in full. We are not seeking approval of the exercise of the Pre -FundedWarrants. The Series A Warrants are not currently exercisable, will be exercisable following the Warrant Stockholder Approval (as described below) and will expire two and one -half(2.5) years thereafter. If a registration statement registering the resale of the shares of common stock underlying the Series A Warrants is not effective or available following the date of Warrant Stockholder Approval, the holder may, in its sole discretion, elect to exercise the Series A Warrants through a cashless exercise. The Series A Warrants also include a zero exercise price provision (referred to in the text of the Series A Warrants as an “alternative cashless exercise”) where, following the Warrant Stockholder Approval (even if a registration statement registering the issuance or resale of shares of common stock underlying the Series A Warrant is effective), the holder of a Series A Warrant has the right to receive, without paying any additional cash or consideration to the Company, an aggregate number of shares of common stock equal to the product of (x) the aggregate number of shares of common stock that would be issuable upon a cash exercise of the Series A Warrant multiplied (which is subject to adjustment, as described below, to a number of shares that is up to 10 times the number of shares underlying the Series A Warrant at issuance) by (y) three (3.0). As a result of these zero exercise price provisions, it is unlikely investors would choose to cash exercise the Series A Warrants, and we are unlikely to receive any cash proceeds from the exercise of the Series A Warrants. Similarly, as a result of the zero exercise price provisions, it is unlikely investors would choose to exercise the Series A Warrants on a “net” or “cashless” basis that would